PremiumCompany AnnouncementsMaxCyte Announces Change in Voting Rights Structure BlackRock Increases Stake in MaxCyte to 9.98% MaxCyte Expands Stock Capital Amidst Strategic Growth PremiumCompany AnnouncementsBlackRock Increases Stake in MaxCyte, Boosting Voting Rights BlackRock Increases Stake in MaxCyte to 7.65% MaxCyte Announces Change in Major Shareholder Holdings PremiumRatingsMaxCyte’s Strong Execution and Strategic Measures Earns Buy Rating Amid Market Challenges MaxCyte reports Q1 EPS (10c), consensus (10c) MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip